Supernus Pharmaceuticals Inc (NASDAQ:SUPN) – Stock analysts at Piper Jaffray Companies boosted their Q3 2018 earnings estimates for Supernus Pharmaceuticals in a research report issued on Wednesday, August 8th. Piper Jaffray Companies analyst D. Amsellem now forecasts that the specialty pharmaceutical company will post earnings of $0.49 per share for the quarter, up from their prior forecast of $0.46. Piper Jaffray Companies has a “Hold” rating and a $44.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Supernus Pharmaceuticals’ Q4 2018 earnings at $0.48 EPS, Q1 2019 earnings at $0.52 EPS, Q2 2019 earnings at $0.63 EPS, Q3 2019 earnings at $0.63 EPS, Q4 2019 earnings at $0.70 EPS, FY2019 earnings at $2.07 EPS and FY2020 earnings at $3.33 EPS.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.43 by $0.14. The business had revenue of $99.54 million for the quarter, compared to analysts’ expectations of $101.01 million. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%.

SUPN has been the topic of several other research reports. ValuEngine upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 12th. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 5th. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 16th. Stifel Nicolaus boosted their price target on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, May 25th. Finally, Jefferies Financial Group boosted their price target on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $54.09.

Shares of SUPN stock opened at $46.15 on Friday. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of 36.63 and a beta of 0.97. Supernus Pharmaceuticals has a 52 week low of $33.30 and a 52 week high of $61.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 4.74 and a current ratio of 2.74.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Everence Capital Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $205,000. Cim LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $207,000. NumerixS Investment Technologies Inc purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $204,000. Reliance Trust Co. of Delaware purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $243,000. Finally, Hartford Investment Management Co. purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $267,000. Hedge funds and other institutional investors own 98.01% of the company’s stock.

In other news, CFO Gregory S. Patrick sold 35,000 shares of the company’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $56.63, for a total transaction of $1,982,050.00. Following the sale, the chief financial officer now directly owns 75,975 shares in the company, valued at approximately $4,302,464.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 7,868 shares of the company’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $57.93, for a total transaction of $455,793.24. Following the sale, the vice president now owns 7,868 shares in the company, valued at $455,793.24. The disclosure for this sale can be found here. Insiders have sold a total of 117,868 shares of company stock worth $6,600,620 over the last 90 days. Corporate insiders own 6.20% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Recommended Story: Price to Earnings Ratio (PE)

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.